A study performed at the University of São Paulo’s Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungunya virus and yellow fever virus.
“Human cells infected by chikungunya virus were treated with sofosbuvir, and the drug eliminated the virus without damaging any cells. The drug proved to be 11 times more effective against the virus than against cells,” said Rafaela Milan Bonotto, a coauthor of the study.
An article on the study, signed by Bonotto, Freitas-Junior and collaborators, can be found on the open platform F1000Research. An article on the group’s research relating to yellow fever will be published shortly.
The discovery is highly significant for public health, as a chikungunya epidemic has been forecast for the coming two years in Brazil.
“Drug development is extremely costly and time-consuming. The process takes 12 years on average between the start of research and bringing the drug to market. The cost is on the order of US$1.5 billion or more,” Freitas-Junior said. “Sofosbuvir has been fully approved for human use. This means it can be readied for use against chikungunya in one to three years, for a much lower cost, estimated at approximately US$500,000.”
He noted that chikungunya is a severe disease not only owing to the acute episode itself – causing symptoms similar to those of dengue – but because it can cause complications that include highly debilitating joint pain lasting months or years. The patient may become incapacitated, unable to work and even bedridden.
“So far we have no vaccine, and our diagnostic tools need to be optimized,” he continued. “Sofosbuvir is something concrete that could become a powerful weapon against this virus. The results of our research could enable any interested institutions to begin clinical trials.”
Bonotto said, “We don’t yet know exactly how the drug works in molecular terms. What we discovered was the macroscopic result: elimination of the virus and preservation of cells. The drug has proven effective in treating hepatitis C because it inhibits the protein that synthesizes the viral genome. The same may happen in the case of chikungunya, but the action mechanism must be elucidated.”
The Latest on: Sofosbuvir
via Google News
The Latest on: Sofosbuvir
- Is Malaysia facing a US sanction on generic Hepatitis C drug? on February 19, 2019 at 4:30 pm
On Feb 11, Médecins Sans Frontières, also known as Doctors without Borders (MSF), submitted a letter of support to the Ministry of Health (MoH) on the issuance of a government license on Sofosbuvir, a ... […]
- Antivirals Improve Outcomes in HCV-Infected Cancer Patients on February 14, 2019 at 10:12 pm
As described here, the outcomes in HCV-infected cancer patients with NHL were greatly improved with antiviral therapeutic agents based on sofosbuvir. The results from an observational study in 153 con... […]
- Researchers Prove Drug Efficacy Against Chikungunya Fever on February 12, 2019 at 7:34 am
Researchers at Fiocruz, in Rio de Janeiro, have proved the efficacy of the drug Sofosbuvir against Chikungunya fever. The study, which has just been published in Antimicrobial Agents and Chemotherapy, ... […]
- Japan Okays Approves Gilead Sciences' Epclusa on January 7, 2019 at 10:18 pm
(RTTNews) - Gilead Sciences Inc. (GILD) said that Japan's Ministry of Health, Labour and Welfare or MHLW has approved Epclusa (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for adults wi... […]
- Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) on January 7, 2019 at 10:16 pm
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for ... […]
- Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) on January 7, 2019 at 10:14 pm
- Epclusa is the First Approved Treatment for Adults with Chronic Hepatitis C Virus with Decompensated Cirrhosis in Japan - Gilead Sciences, Inc. (GILD) announced today that Japan’s Ministry of Health ... […]
- Sofosbuvir rids organism of chikungunya and yellow fever viruses on December 19, 2018 at 4:53 am
A study performed at the University of São Paulo's Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungun... […]
- Sofosbuvir rids organism of chikungunya and yellow fever viruses on December 18, 2018 at 3:34 pm
Sofosbuvir is already used to treat hepatitis C and has passed all human use approval tests, so it can be fairly easily deployed if the chikungunya epidemic forecast for the next two years materialize... […]
- Hepatitis Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Have Not Been Treated on December 6, 2018 at 10:29 am
People living with hepatitis C, access to medicines activists, and the medical community around the world "mark" the fifth birthday of the first all-oral, one dose per day cure sofosbuvir (Sovaldi®), ... […]
- China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6 on December 4, 2018 at 5:52 am
--Harvoni Offers Highly Effective, Short-Duration, Pan-Genotypic Treatment for Chinese Patients with HCV Infection-- --Harvoni Achieved Cure Rate (SVR12) of 100 Percent in Clinical Trial of Chinese Pa... […]
via Bing News